Bevacizumab is one of the most widely used anti-angiogenic drugs in oncology, but the overall beneficial effects of this VEGF-A targeting agent are relatively modest, in part due to the lack of a biomarker to select patients most likely to respond favorably. Several molecular aberrations in cancer influence angiogenesis, including mutations in the tumor suppressor gene TP53 which occur frequently in many human malignancies. In this study, we present a multiple regression analysis of transcriptomic data in 123 patients with non-small-cell lung cancer (NSCLC) showing that TP53 mutations are associated with higher VEGF-A expression (p=0.006). This association was interesting given a recent retrospective study showing longer progression-free survival in patients with diverse tumors who receive bevacizumab, if tumors harbor mutant TP53 instead of wild-type TP53. Thus, our current findings linking TP53 mutation with VEGF-A upregulation offered a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53. Overall, this work warrants further evaluation of TP53 as a ready biomarker to predict bevacizumab response in NSCLC and possibly other tumor types.
Introduction
Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths (1) , and represents a heterogeneous group of neoplasms, mostly squamous cell and adenocarcinoma. A diagnosis of NSCLC carries a grim prognosis; five-year survival is less than 15%(2).
Bevacizumab is an antibody that targets vascular endothelial growth factor-A (VEGF-A).
Bevacizumab combined with carboplatin and paclitaxel has been approved for the initial treatment of unresectable NSCLC, based on a two-month increase in survival (12.3 versus 10.3 months) when compared to the chemotherapy alone (3) . Bevacizumab is also used in the treatment of renal and colon cancer and glioblastoma multiforme, with similar modest benefits; its approval for breast cancer was recently revoked by the US FDA. The relatively small impact of bevacizumab on outcome may be due to the fact that a subset of patients responds, while others derive no salutary effects or, conceivably, might even be harmed by bevacizumab. Yet, no biomarker for patient selection has been identified. This is especially important because bevacizumab can have serious toxicity, including hypertension and bowel perforation; it is also extremely expensive, costing about 40,000 to 100,000 dollars per year (4) .
Of interest in this regard, we recently reported, in a retrospective study of patients with diverse cancers, that use of bevacizumab-containing regimens predicted for longer progressionfree survival (PFS) in TP53-mutant tumors (multivariate analysis (p<0.001) (PFS = 11 versus 5.0 months; mut versus wt TP53))(5). The mechanism by which this correlation might occur remains unclear. However, several studies suggest a role for TP53 in angiogenesis (6, 7) . Importantly in this regard, though early data failed to find a clear association between VEGF expression and outcome after bevacizumab administration, recent data using improved technology suggest that circulating levels of the short isoform of VEGF-A is a strong biomarker candidate for predicting benefit (8) .
Herein, we report that, in a transcriptomic evaluation of NSCLC (2) , multiple regression analysis showed that VEGF-A expression correlated independently with TP53 mutational status.
These data link TP53 mutations directly with VEGF-A, the primary target of bevacizumab, and suggest that TP53 status merits further exploration as a biomarker for bevacizumab response in NSCLC as well as in additional neoplasms.
Research. 
Results and Discussion
Our study population (N=123) was comprised of 57 patients with adenocarcinoma of the lung (46%); 50, squamous cell (41%); 13, large cell (11%); and 3, unclassified cases (3%).
Testing for aberrations in the TP53, KRAS, EGFR, BRAF, PIK3CA and ERBB2 genes revealed the following rates of abnormalities: TP53 (N=31 (25%) (24.6% of adenocarcinoma versus 28.6% of squamous cell; p=0.665)) (Supplemental Results); KRAS (N=20 (18%)); EGFR (N=13 (12%)); PIK3CA (N=2); BRAF and ERBB2 (N=1 each) (Supplemental Table 1 ).
In univariable analysis, transcriptomic data (84 gene products; Supplemental Table 2) showed differential expression as follows: median fold changes of tumor versus normal tissues (Table 1) .
Using VEGF-A as the dependent variable, in a multiple linear regression analysis including TP53, KRAS, and EGFR (all mut versus wt); histology (adenocarcinoma versus squamous); and the other genes found differentially expressed (BAX, mTOR APAF1, and AREG) as variables, the only statistically significant independent predictor for VEGF-A expression was TP53 mutational status (p=0.006) ( Table 2) . When forward and backward regression analyses were performed, both tests confirmed that TP53 mutation was the best independent predictor for higher VEGF-A levels (p=0.008). Segregating by histology, a multiple regression analysis demonstrated that TP53 mutational status was the only independent factor predicting increased VEGF-A expression in adenocarcinoma (p=0.007) but not in squamous cell 
carcinoma (p=0.599), consistent with the observation that expression levels of VEGF-A were significantly higher in TP53-mutated specimens in adenocarcinoma (median 5.95 versus 3.0; p = 0.012), but not in squamous cell carcinoma (median 3.9 versus 3.1; p = 0.636, Supplemental Table 3 ). This difference between adenocarcinoma and squamous cell carcinoma suggest the complexity of the mechanisms involving TP53 and angiogenesis regulation, and illustrates possible mechanistic differences between tissues.
Angiogenesis plays a critical role in the growth and spread of cancer, as the resulting new blood vessels supply the tumor with needed nutrients and oxygen; VEGF is probably the most commonly involved pro-angiogenic factor (9) . Our data complement previous preclinical data in NSCLC correlating either aberrant TP53 expression with higher VEGF level(10) (measured by quantitative reverse transcription polymerase chain reaction), or TP53 gene mutations with a strongly positive VEGF immunoreactivity (11) . Further, wt TP53 indirectly represses VEGF promoter activity by inhibiting transcription factors, e.g., SP1 and E2F; there is also a TP53-binding site adjacent to the hypoxia inducible factor-1alpha (HIF-1alpha) binding site that resides within the VEGF promoter, and is essential for VEGF induction during hypoxia (12) . In addition, Narendran A et al. (8) showed that transfection of stromal cells with mutant p53 increased synthesis of VEGF. These mechanistic data are consistent with our observation of high VEGF-A transcripts in the presence of mutant TP53. BAX transcript levels were also higher in tumors harboring mutant TP53 ( Table 1) Using gene expression profiling techniques, prior studies also demonstrated that adenocarcinoma and squamous cell NSCLC have different expression portfolios (2, 14) , which is in line with our observation that the association between TP53 mutations and increased VEGF-A transcripts appears specific for adenocarcinoma of the lung. It is conceivable that the improved outcome that was previously reported by our group(5) in bevacizumab-treated patients who harbored TP53 mutations versus wild type TP53 is due to the association between TP53 mutations and higher VEGF-A, the target for bevacizumab. But this association may not hold true for all tumor types. For instance, benefit from bevacizumab could not be correlated with TP53 status in metastatic colorectal cancer (15, 16) . On the other hand, these prior studies in colorectal cancer had significant differences in methodology that might have influenced The salutary effects of anti-angiogenic therapy can differ dramatically, depending on the cancer type. For the majority of tumors, bevacizumab must be combined with other drugs to show benefit. Few responses are observed with monotherapy(9). One exception is ovarian cancer, where monotherapy with bevacizumab can achieve response rates in the 16-21% range even in advanced disease (17) . One of the most responsive subsets of ovarian cancer is the highgrade serous histology. Of interest in this regard, TP53 mutations are a hallmark of these tumors, with a frequency exceeding 90% (18) . In sharp contrast, prostate carcinomas, with a rather low Bevacizumab has previously been hailed as the best-selling drug in oncology. However, for most cancers in which it is used, including NSCLC, renal, and colon cancer as well as glioblastoma multiforme, bevacizumab increases survival by only a couple of months.
Furthermore, the FDA recently acted to rescind its approval in breast cancer because of lack of proof a survival advantage, despite previous evidence of some activity in this disease (8) . Most likely, in relevant malignancies, a subgroup of patients is responsive to bevacizumab, but a biomarker defining this subset has remained elusive. TP53 mutations are found in diverse cancers, and 25% of our NSCLC patients had a TP53 alteration. Indeed, TP53 is one of the most commonly aberrant genes across tumors, yet there is no approved therapy that targets it. Our data have previously suggested a clinical association between TP53 mutations and better PFS after bevacizumab treatment(5). Our current observations show that TP53 mutations are an independent predictor of high expression of VEGF-A, the primary target of bevacizumab. These
